Pharmaust Limited (AU:PAA) has released an update.
PharmAust Limited has issued 215,000 new shares as a result of exercising unlisted options at $0.10 each, in a move not requiring investor disclosure under certain Australian legal guidelines. In parallel, the biotech firm is making strides in neurodegenerative disease treatment, with positive Phase 1 trial results for its drug MPL in ALS patients. The company anticipates participating in a key trial that could fast-track FDA approval for MPL by 2026, against a backdrop of a rapidly growing neurodegenerative disease market.
For further insights into AU:PAA stock, check out TipRanks’ Stock Analysis page.
